Mesenbio, a University of York spin-out, has raised funds from DSW Ventures, NG Bio, and grant funding from Innovate UK in an investment round.
The treatment targets rheumatoid arthritis, affecting nearly half a million people in the UK, with a focus on reducing inflammation and regenerating damaged tissue using stem cell therapies.
Prof Paul Genever and Dr David Kuntin founded Mesenbio based on their work at the University of York’s Biomedical Research Institute, and the funding will allow them to create new roles, develop manufacturing processes, conduct pre-clinical studies, and prepare for clinical trials.
Research on extracellular vesicles (EVs) from human stem cells has shown promising results in laboratory tests, with potential to not only alleviate pain but also repair tissue damage.
Mesenbio’s CEO, Dr David Kuntin, emphasized the method’s scalability and its potential to halt tissue damage, repair tissue, and restore the immune system to normal levels, with the goal of advancing to human trials.
Mesenbio becomes the twelfth company to join DSW Ventures portfolio, and the first from its recently-launched Seed EIS fund.
Doug Quinn of DSW Ventures expressed optimism about the funding enabling progress towards a treatment for rheumatoid arthritis.
Jason Goldstein, co-founder at NG Bio, highlighted Mesenbio’s unique technology and the team’s potential for addressing the problem of rheumatoid arthritis.
Versus Arthritis, the biggest investor in arthritis research in the UK, has funded Mesenbio’s research, showing support for the development of important arthritis treatment.